PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling

Metastatic prostate cancer (PCa) has high mortality and a poor 5-year survival rate primarily due to the lack of effective treatments. Bone is the primary site of PCa metastasis in humans and the development of reliable therapeutic options for bone metastatic PCa will make a huge impact in reducing...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochem Pharmacol
Hauptverfasser: Verma, Arti, Artham, Sandeep, Alwhaibi, Abdulrahman, Adil, Mir S., Cummings, Brian S., Somanath, Payaningal R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7414983/
https://ncbi.nlm.nih.gov/pubmed/32240651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2020.113943
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge